New York Senate Bill J02069

New York 2025-2026 Regular Session

• Introduced: 5/8/26
• Refer: 5/8/26
• Report Pass: 5/12/26
• Passed: 5/12/26

Caption

Memorializing Governor Kathy Hochul to proclaim May 10-16, 2026, as Prevention Week in the State of New York

Summary

This resolution memorializes Governor Kathy Hochul to proclaim May 10-16, 2026, as Prevention Week in New York State, in conjunction with National Prevention Week. It frames the observance as a public education effort to raise awareness about substance use and misuse, mental health concerns, and the work of prevention organizations and community partners. The resolution highlights the opioid and overdose crisis, including fentanyl, and emphasizes prevention, harm reduction, and access to resources. It specifically references community education, school participation, and the role of state and federal agencies such as SAMHSA and the New York State Office of Alcoholism and Substance Abuse Services in promoting prevention campaigns and support services.

Impact

As a resolution, this measure does not change substantive state law or create new regulatory requirements. Its practical effect is symbolic and promotional: it asks the Governor to issue a proclamation and encourages public awareness activities, partnerships, and dissemination of prevention resources related to substance use, overdose prevention, and mental health.

Sentiment

The overall sentiment is strongly supportive and noncontroversial. The resolution presents prevention efforts as broadly beneficial to public health, safety, and community awareness, and it praises the work of prevention providers, schools, and public agencies. No votes or committee transcripts were provided, but the text itself reflects unanimous, affirmative messaging around prevention and education.

Contention

There is little evident contention in the resolution itself because it is commemorative rather than regulatory. The only substantive policy emphasis is on how to address substance use and overdose risk, including references to harm reduction tools such as naloxone, fentanyl test strips, syringe services, and medication for opioid use disorder. Those topics can sometimes be debated in broader policy settings, but no opposing views are reflected in the available record.